Search
Lyell Immunopharma Inc
LYELAdd to Watchlist
12.750USD
-0.090-0.70%
Close 07-23 16:00（ET）Quotes delayed by 15 min
297.43MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Lyell Immunopharma Inc is 7.67, ranking 275 out of 386 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 45.00 and a low of 12.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
38.143
Target Price
+190.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Lyell Immunopharma Inc
LYEL
7
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lyell Immunopharma Inc's expected revenue for the next quarter?
Lyell Immunopharma Inc's expected revenue is 3.83K.
What is Lyell Immunopharma Inc's price target?
Analysts forecast that Lyell Immunopharma Inc's price target is USD 25.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 12.00.
How have Lyell Immunopharma IncLYEL's recent earnings per share performed?
The market expectation was USD -1.10, while Lyell Immunopharma IncLYEL's earnings per share (EPS) for the previous quarter was USD -6.86. EPS for the next quarter is expected at USD -2.02.
What is the analyst rating for Lyell Immunopharma Inc?
Based on the ratings of Lyell Immunopharma Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.